Kite Pharma (KITE) : Wednesdays money flow data in Kite Pharma (KITE) suggests that the bulls made the most of the weakness in the stock. The inflow of money into the stock on upticks was $4.51 million, whereas, $4.01 million worth of transactions were done on downticks. The ratio between the two, uptick and downtick stood at 1.13, in favor of the bulls. The total money flow into the stock was $0.5 million clearly indicating that the smart money has been buying into the stock on weakness.
In comparison, the money flow in block deals was $1.2 million. The total value of block trades done on upticks was $1.2 million. Kite Pharma (KITE) fell $1.41 and traded at $58.63, down -2.35% for the day, over previous days close. On a weekly basis, the shares are 7.44% over the previous weeks close.
Shares of Kite Pharma, Inc. appreciated by 1.58% during the last five trading days but lost 2.72% on a 4-week basis. Kite Pharma, Inc. is up 10.73% in the last 3-month period. Year-to-Date the stock performance stands at -8.37%.
Kite Pharma (KITE) : Zacks Investment Research ranks Kite Pharma (KITE) as 3, which is a Hold recommendation. 7 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 other analysts are mildly bullish on the stock and favor a Buy. A total of 1 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 9 research analysts is 1.33, which indicates as a Strong Buy.
Kite Pharma (NASDAQ:KITE): stock was range-bound between the intraday low of $55.9 and the intraday high of $60.4 after having opened at $60.4 on Wednesdays session. The stock finally closed in the red at $60.4, a loss of -5.96%. The stock remained in the red for the whole trading day. The total traded volume was 2,196,888 shares. The stock failed to cross $60.4 in Wednesdays trading. The stocks closing price on Thursday was $60.04.
Kite Pharma, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Company does this using its engineered autologous cell therapy (eACT), which is an approach to the treatment of cancer. eACT involves the genetic engineering of T cells to express either chimeric antigen receptors (CARs) or T cell receptors (TCRs). It is conducting a Phase II clinical trial of a TCR-based therapy and multiple Phase I-IIa clinical trials of CAR- and TCR-based therapies. The Companys lead product candidate KTE-C19, is a CAR-based therapy, for the treatment of refractory diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL). It is developing a pipeline of eACT-based product candidates for the treatment of advanced solid and hematological malignancies: CD19CAR, KTE-C19CAR and EGFRvlll CAR, among others.